About Cti biopharma
CTI BioPharma is a biopharmaceutical company that specializes in the development, acquisition, and commercialization of therapies for blood-related cancers. The company's mission is to provide unique benefits to patients suffering from these types of cancers by developing innovative treatments that target specific cancer cells.
The company was founded in 1991 and has since then been dedicated to improving the lives of patients with blood-related cancers. CTI BioPharma has a team of experienced professionals who are committed to discovering new treatments for these diseases.
One of the key areas of focus for CTI BioPharma is myeloproliferative neoplasms (MPNs), which are a group of rare blood disorders that affect the bone marrow. These disorders can lead to an overproduction of certain types of blood cells, which can cause serious health problems.
CTI BioPharma's lead product candidate, pacritinib, is currently being developed as a treatment for MPNs. Pacritinib works by inhibiting certain enzymes that are involved in the growth and survival of cancer cells. This makes it an effective treatment option for patients with MPNs who have failed other therapies or who cannot tolerate them.
In addition to pacritinib, CTI BioPharma has several other product candidates in its pipeline. These include PIXUVRI®, which is approved in Europe as a treatment for aggressive B-cell non-Hodgkin lymphoma (NHL), and TRISENOX®, which is approved in the United States as a treatment for relapsed or refractory acute promyelocytic leukemia (APL).
CTI BioPharma also has partnerships with other companies and organizations that share its commitment to developing innovative treatments for blood-related cancers. For example, it has partnered with Servier Pharmaceuticals on the development and commercialization of PIXUVRI® outside Europe.
Overall, CTI BioPharma is an innovative biopharmaceutical company that is dedicated to improving the lives of patients with blood-related cancers through its research and development efforts. With its experienced team and promising pipeline products like pacritinib, it looks set to continue making significant contributions towards this goal well into the future.